Adagene (FRA:978) Other Current Receivables: €0.02 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:978 Adagene Inc FRA:978
42 GF Score
Price €3.10
GF Value €12.17
! 3 Warning Signs
View Full Analysis

What is Adagene Other Current Receivables?

Adagene FRA:978 +1.31% 42 Other Current Receivables is €0.02 Mil as of Dec. 2025. GuruFocus rates FRA:978 with a GF Score™ of 42/100 and a GF Value™ of €12.17. The stock has 3 warning signs investors should review.

Adagene's Other Current Receivables for the quarter that ended in Dec. 2025 was €0.02 Mil.

Adagene's quarterly Other Current Receivables declined from Dec. 2024 (€0.01 Mil) to Jun. 2025 (€0.00 Mil) but then increased from Jun. 2025 (€0.00 Mil) to Dec. 2025 (€0.02 Mil).

Adagene's annual Other Current Receivables declined from Dec. 2023 (€0.20 Mil) to Dec. 2024 (€0.01 Mil) but then increased from Dec. 2024 (€0.01 Mil) to Dec. 2025 (€0.02 Mil).

Adagene Other Current Receivables Related Terms

Adagene Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Adagene's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adagene Other Current Receivables Chart

Adagene Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial 3.99 0.58 0.20 0.01 0.02

Adagene Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.20 0.03 0.01 0.00 0.02
FRA:978
42GF Score
Adagene Inc FRA:978
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adagene Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of €0.02 Mil mean?
Adagene (FRA:978) has a Other Current Receivables of €0.02 Mil as of Dec. 2025. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Adagene and its competitors.
Is Adagene's Other Current Receivables too high?
Adagene's current Other Current Receivables is €0.02 Mil. Overall, Adagene has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Adagene's Other Current Receivables compare to RNAC and LYEL?
Adagene's Other Current Receivables of €0.02 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Adagene and its competitors. Adagene's current Other Current Receivables is €0.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adagene stock overvalued right now?
Adagene (FRA:978) has a current Other Current Receivables of €0.02 Mil. The stock's GF Value™ is €12.17, compared to a current price of €3.10 — trading 74.5% below its estimated fair value. The current Other Current Receivables is €0.02 Mil. Adagene's overall GF Score™ is 42/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Adagene (FRA:978), the current Other Current Receivables is €0.02 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Adagene (FRA:978) Overvalued in 2026?

Based on GuruFocus' analysis, Adagene stock appears to be undervalued. The current stock price of €3.10 is trading 74.5% below its estimated GF Value™ of €12.17.

Key valuation signals for FRA:978:

  • Other Current Receivables: €0.02 Mil
  • GF Value™: €12.17 vs. price of €3.10 (74.5% below fair value)
  • GF Score™: 42/100 with 3 warning signs

No single metric tells the full story. See the FRA:978 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Adagene Business Description

Other Exchanges ADAG:USA
Address Xinghu Street, Suzhou Industrial Park, 4th Floor, Building C14, No. 218, Jiangsu Province, Suzhou, CHN, 215123
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.
42GF Score

Get the complete analysis for FRA:978

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.10
Price
€12.17
GF Value